CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 9 enrolled
Drug / intervention
Fludarabine +2 moredrug
Likely dose
Fludarabine 30 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00427336
NCT00427336N/ACompleted

Purine Analog-Based Conditioning for Allogeneic Stem Cell Transplantation in Patients With Severe Aplastic Anemia

M.D. Anderson Cancer Center·interventional·Posted Jan 29, 2007·Updated Oct 27, 2011

In Brief

A clinical study evaluating Fludarabine, Cyclophosphamide, and 1 other intervention for Aplastic Anemia. Completed, enrolled 9 participants across 1 site.

Detailed Summary

Primary Objectives: 1. To determine the feasibility and toxicity of employing purine-analog based conditioning for allogeneic donor stem cell transplantation in patients with severe aplastic anemia (AA). 2. To determine the engraftment kinetics and degree of chimerism that can be achieved with this strategy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAplastic Anemia
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 29, 2007
Enrollment StartDec 1, 2000
Primary CompletionAug 1, 2009
TodayJul 2, 2026
Enrollment to primary: 8.7 yearsPosted 19.4 years ago

Interventions

Fludarabinedrug

30 mg/m\^2 by vein daily over 30 minutes

Cyclophosphamidedrug

300 mg/m\^2 by vein daily over 2 hours

Antithymocyte Globulindrug

3.75 mg/kg by vein daily over 4 hours